ArticleWomen & health2025
Prevalence of hypertensive disorders of pregnancy and chronic hypertension increased throughout the COVID-19 pandemic in South Carolina (2015-2021).
Article in Women & health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hypertensive disorders of pregnancy (HDP) and chronic hypertension (CHTN) are related to maternal and infant morbidity and mortality. We aimed to assess HDP and CHTN prevalence changes before (January 2015-February 2020) and during the COVID-19 pandemic (March 2020-December 2021) in South Carolina (SC). SC live births (2015-2021) were included (194,841 non-Hispanic White [NHW]); 108,195 non-Hispanic Black [NHB]; 25,560 Hispanic; 16,346 other race/ethnicity). Linked birth certificate and hospitalization/ED data was used. Relative risks (RRs) and 95 percent CIs adjusted for potential confounders estimated HDP and CHTN risk before and during the pandemic. HDP risk is associated with a one-year increase in calendar time pre-pandemic differed by race/ethnicity. Corresponding RRs (95 percent CIs) were 1.06 (1.05-1.06) in NHW, 1.07 (1.06-1.07) in NHB, 1.07 (1.06-1.09) in Hispanic and 1.09 (1.07-1.12) for other races/ethnicities. During the pandemic, RRs (95 percent CIs) attenuated slightly remaining significant (NHW, 1.03 [1.01-1.04]; NHB, 1.04 [1.02-1.05]; Hispanic, 1.04 [1.02-1.07]; other races/ethnicities, 1.06 [1.04-1.09]). Increasing race-ethnic group-specific trends from 2015 to 2021 were reported for CHTN (NHW, 1.09 [1.08-1.10]; NHB, 1.09 [1.08-1.10]; Hispanic, 1.08 [1.05-1.12]; other races/ethnicities, 1.15 [1.11-1.19]). HDP and CHTN's increasing prevalence from 2015 to 2021 differed by race/ethnicity, with HDP impacted by the pandemic and upward trends observed for both conditions after adjustment. Screening, diagnostic, and reporting practices across different data sources and actual changes may impact HDP and CHTN prevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.